Introduction 1

Epstein-Barr virus (EBV) causes lymphocyte-proliferative diseases in immune-deficient 2
patients, and is associated with Burkitt's lymphoma, Hodgkin's lymphoma, other B-and 3 T-cell lymphomas, anaplastic nasopharyngeal carcinoma, and some gastric carcinomas 4 (for review, see ref.
1). EBV infection in vitro converts primary human B cells into 5
continuously proliferating lymphoblastoid cell lines (LCLs) (2) . In LCLs, EBV expresses 6 six nuclear proteins (EBV nuclear antigens EBNA1, -2, -3A, -3B, -3C, and -LP), three 7 integral membrane proteins (LMP1, -2A, and -2B), two small non-polyadenylated RNAs 8 (EBER1 and EBER2), and Bam A rightward transcripts (for review, see ref.
3). Six of 9 these viral latency proteins, EBNA1, -2, -3A, -3C, -LP, and LMP1, are absolutely or 10 critically required for the transformation phenotype (3) . 11 EBNA3A, EBNA3B, and EBNA3C, which are arranged in tandem in the EBV genome, 12 are encoded by genes that are similar in structure (4-8), leading to the proposal that the 13 EBNA3 genes may have arisen from a tandem triplication of an ancestral gene (9-11). 14 The N-terminal amino acids of EBNA3A, EBNA3B, and EBNA3C mediate interaction 15 with a sequence-specific DNA-binding protein, RBP-Jκ (12) (13) (14) (15) (16) . Reverse genetic 16 experiments with recombinant EBVs indicate that EBNA3A and EBNA3C are essential 17 for the EBV-mediated conversion of primary B cells into LCLs, whereas EBNA3B is 18 dispensable (17) (18) (19) (20) . The role of EBNA3C in LCL outgrowth and continuous proliferation 19 has been only partially delineated, but, using transient transfection reporter assay, 20 EBNA3C has been shown to play a complex regulatory role in the transcription of viral 21 and cellular genes (21-26). EBNA3C has also been shown to interact with histone 22 deacetylase and with the corepressor CtBP (27-29). In addition to its transcriptional 23 expression were similar in the absence or presence of 4HT (Fig. 3A) . The levels of 13 CD21 and CD23 expression on the surfaces of LCLs were also indistinguishable under 14 both conditions (Fig. 3B) . Therefore, E3C-HT inactivation seems to affect the growth of 15
LCLs without changing the expression of other critical viral latent proteins, or c-myc. 16
EBNA3C inactivation results in a decrease of cells in S and G 2 /M, which is 17
accompanied by a decrease in hyperphosphorylated pRb. The effect of E3C-HT 18 inactivation on the cell cycle distribution of LCLs was assessed (Fig. 4A) . In 4HT-19 containing medium, 54% of E3C-HT LCLs were in G 0 /G 1 , 25% in S, 13% in G 2 /M, and 20 8% in SubG 1 . Cell cycle profile of E3C-HT LCLs in the presence of 4HT was unchanged 21 with time (data not shown). When LCLs were cultured in medium without 4HT, the 22
proportions of cells in S and G 2 /M progressively fell to 5% and below 3%, respectively, 23 and the proportion in SubG 1 progressively increased to 31% (Fig. 4A ). Growth and cell 24 cycle distribution of wild-type LCLs did not change in the absence or presence of 4HT, 1 indicating that 4HT itself has no effect on cell cycle entry and cell survival ( Fig. 2B and  2 data not shown). Thus, EBNA3C inactivation inhibits cell cycle progression and results in 3 an increase in the percent of hypodiploid cells. Western blot analysis showed that a 4 fraction of pRb was consistently hyperphosphorylated in the presence of 4HT. By 5 contrast, in the absence of 4HT, hyperphosphorylated pRb progressively diminished (Fig.  6 4B). The expression levels of hypophosphorylated pRb were similar in the absence and 7 presence of 4HT (Fig. 4B , short exposure). Therefore, EBNA3C inactivation decreases 8 cell cycle progression, which is accompanied by a decrease in hyperphosphorylated 9 forms of pRb. 10
EBNA3C inactivation results in the accumulation of p16
INK4A . Since EBNA3C 11 inactivation caused a decrease in pRb phosphorylation, we examined the effect of 12 EBNA3C inactivation on the expression of cyclin-dependent kinase (Cdk) inhibitors. 13
Western blot analysis showed that the p16
INK4A protein accumulated in E3C-HT LCLs 14 that were cultured in medium without 4HT (Fig. 5A ). The expression of cyclin A gradually 15 decreased after EBNA3C inactivation (Fig. 5A ). In contrast, we did not see any clear 16 differences in the expression of p21 and p27 in the absence or presence of 4HT (Fig.  17 
5A). p16
INK4A did not accumulate in the E3C-HT LCLs that were transfected with an oriP 18 plasmid expressing wild-type EBNA3C and cultured in medium without 4HT, indicating 19 that heterologous expression of EBNA3C prevents the accumulation of p16 INK4A in LCLs 20 (Fig. 5B) . Real-time RT-PCR analysis revealed that the level of p16
INK4A transcript was 21 higher in the absence of 4HT than in its presence and that it progressively increased 22 after EBNA3C inactivation. Thus, the accumulation of p16 INK4A occurs at the mRNA level 23 (Fig. 5C ). Since p16
INK4A was previously shown to disrupt cyclin D/Cdk4, 6 kinase 24 complexes (40, 41), Cdk4 complexes in E3C-HT LCLs were analyzed in the absence 1 and presence of 4HT. Lysates prepared from LCLs cultured with or without 4HT were 2 immunoprecipitated with an anti-Cdk4 antibody. The immunoprecipitates were then 3 subjected to Western blot analysis with anti-p16 and anti-cyclin D2 antibodies. We 4 examined cyclin D2, but not cyclin D1, because it had been reported that cyclin D1 is not 5 detected in LCLs (42). The expression levels of Cdk4, Cdk6, and cyclin D2 in the LCL 6 lysates were similar in the absence or presence of 4HT (Fig. 5D ). Almost identical 7 amounts of Cdk4 were immunoprecipitated from LCLs cultured with or without 4HT. 8
Cdk4 complexes from LCLs cultured without 4HT contained p16
INK4A , but Cdk4 9 complexes from LCLs cultured with 4HT did not (Fig. 5D ). In contrast, Cdk4 complexes 10 from LCLs cultured with 4HT contained significantly more cyclin D2 than did LCLs 11 cultured without 4HT (Fig. 5D ). These results indicate that the p16
INK4A that accumulates 12 in LCLs after EBNA3C inactivation physically associates with Cdk4, and that EBNA3C 13 inactivation results in an increase of the p16 INK4A /Cdk4 complex and a decrease of the 14 cyclinD2/Cdk4 complex in LCLs. 15
16
Discussion 1
We established LCLs expressing a conditionally active form of EBNA3C (E3C-HT), a 2 system that allowed us to clarify the physiological role of EBNA3C in LCL growth 3 maintenance. The level of E3C-HT protein gradually diminished in the absence of 4HT, 4
and it was almost undetectable after two weeks of culture without 4HT. Concomitant with 5 the disappearance of E3C-HT, E3C-HT EBV-infected LCLs ceased growing in the 6 absence of 4HT. Moreover, expression of wild-type EBNA3C from a transfected oriP 7 plasmid enabled E3C-HT LCLs to grow in the absence of 4HT. These experiments 8 clearly show that EBNA3C has an essential role in maintaining LCL growth. 9
In LCLs, EBNA3C extensively associates with a cellular transcription factor, RBP-Jκ, 10
and it is presumed to modulate EBNA2-RBP-Jκ-mediated transcription (12) (13) (14) (15) . In 11 transient transfection assays, EBNA3C expression strongly represses the EBNA2-12 mediated activation of the EBV Cp EBNA promoter, and it also activates the EBV LMP1 13 promoter in cooperation with EBNA2 (21-26). However, the effects of EBNA3C on 14 cellular and viral gene expression have never been investigated using a system in which 15 EBNA3C is expressed at physiological levels. The data presented here indicate that 16
EBNA3C inactivation does not clearly affect viral EBNAs or LMP1 expression. c-myc is a 17
well-known EBNA2-regulated gene that has a critical role in LCL growth (37-39). Our 18 data shows that the expression of c-myc is not affected by EBNA3C inactivation in LCLs. 19
Thus, EBNA3C inactivation seems to inhibit LCL growth without affecting the expression 20 of other EBNAs, LMP1, or c-myc. 21
It has been reported that EBNA3C has cell cycle regulatory functions. It was shown 22
that transfection of cells with EBNA3C results in the accumulation of cells in G 2 /M (30). 23
Consistently, our data shows that cells in G 2 /M decreased after EBNA3C inactivation. 1 EBNA3C has also been shown to stimulate cyclin A-dependent kinase activity without 2 dramatically changing the level of cyclin A (30, 31). In our data, however, EBNA3C 3 inactivation caused a decrease in the level of cyclin A. This may be due to the decrease 4 of cells in S and G 2 /M phase after EBNA3C inactivation, because cyclin A is expressed 5 mainly in S and G 2 /M phases (43). Recently, it was reported that EBNA3C recruits the 6 SCF SKP2 ubiquitin ligase complex and mediates the degradation of p27 and pRb (32, 7 33). Both hyperphosphorylated and hypophosphorylated forms of pRb are reduced in 8 EBNA3C-transfected cells (33). However, in our data, there was no obvious increase in 9 p27 or pRb mediated by EBNA3C inactivation in LCLs, whereas hyperphosphorylated 10 pRb was decreased by EBNA3C inactivation. Differences in the expression levels of 11 EBNA3C and/or differences in cell type may be possible explanations for these 12 discrepancies. Alternatively, the increase of hypodiploid cells after EBNA3C inactivation 13 might mask the increase in pRb, because it has been reported that pRb is a substrate of 14 caspases and is degraded in apoptotic cells (44 
EBNA3C directly regulates the expression of p16
INK4A , and the mechanism by which 9
p16
INK4A is induced after EBNA3C inactivation remains to be elucidated. It has been 10 reported that EBNA3C enhances the transformation of rat embryo fibroblasts and 11 relieves p16's suppression of transformation (45). EBNA3C may regulate the p16
INK4A -12
Rb pathway by various mechanisms to maintain the growth of LCLs. 13
Our data also showed that EBNA3C inactivation in LCLs resulted in the increase of 14 hypodiploid cells. This result suggests that EBNA3C contributes to the survival of LCLs. 15
Further investigations are needed to clarify the link between EBNA3C and cell survival. 16
One important finding of our experiments is that EBNA3C has a role in LCL growth that 17 cannot be replaced by EBNA3A or EBNA3B. Transduction of EBNA3C into E3C-HT 18
LCLs prevented growth arrest that was caused by E3C-HT inactivation, whereas the 19 expression of EBNA3A or EBNA3B had no effect. Previous reports of LCLs expressing a 20 conditionally active EBNA3A indicated that EBNA3A, but not EBNA3B or EBNA3C, 21 rescues growth arrest caused by EBNA3A inactivation (16, 19). These results suggest 22 that EBNA3C and EBNA3A have unequivocally distinct functions in supporting LCL 23
growth. 24
Materials and Methods 1
Cell lines. P3HR-1 (clone 16) is a Burkitt's lymphoma cell line that contains a type 2 2 EBV genome. IB4 is an LCL transformed with B95-8 strain EBV. LCLs were maintained 3 in RPMI 1640 medium supplemented with 15% FBS, L-glutamine, streptomycin, 4 penicillin, and with or without 400 nM 4-hydroxytamoxifen (4HT) (Sigma). 5
Plasmids. Two loxP sites of pBS246 (Life Technologies) were replaced with mutated 6 loxP sites (2272 loxP) with synthetic oligonucleotides to construct pBS246-mloxp2272. 7
The blunted FokI-BclI fragment of pcDNA4/HisMax (Invitrogen) containing the zeocin 8 resistance marker gene (zeo) was cloned into the EcoRV site of pBS246-mloxp2272 to 9 make pBS246-mloxp-zeo. A SpeI fragment containing 4-hydroxy-tamoxifen-responsive 10 modified estrogen receptor hormone-binding domain (HTER) from pBSKS+ERTM (a gift 11 of T. Littlewood) was cloned into SpeI site of pBS246-mloxp-zeo to construct pBS246-12 mloxp-zeo-HTER (34). OriP plasmids expressing flag, EBNA3A, EBNA3B, or EBNA3C 13 under the control of SV40 promoter have been described (19). Lytic EBV replication was 14 induced with pSVNaeI Z (19). 15
Construction of E3C-HT EBV BACmid. AK-BAC-GFP derived from a type 1 EBV 16
Akata strain has been described (35). Minipreparation, maxipreparation, and analysis of 17
BACmid DNA have also been described (35). Construction of E3C-HT EBV BACmid 18 was performed in E. coli containing AK-BAC-GFP by Redγ, RecE, RecT (GET) 19 Every 4 to 8 days, viable cell numbers were counted, cultures were split and total viable 14 cell numbers were calculated relative to the initial culture. 15
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